Psychiatry / Mental Health drug pipeline

Depression, schizophrenia, bipolar disorder, ADHD, anxiety. Recent revival driven by neurokinin and psychedelic mechanisms.

Recent approvals (last 30 days)

No approvals in this window.

Upcoming PDUFA dates (next 6 months)

No upcoming decisions in this window.

Top sponsors

1. Shanghai Mental Health Center · 23 drugs
2. Otsuka Pharmaceutical Development & Commercialization, Inc. · 17 drugs
3. New York State Psychiatric Institute · 16 drugs
4. AstraZeneca · 15 drugs
5. Massachusetts General Hospital · 15 drugs
6. Eli Lilly and Company · 12 drugs
7. National Institute of Mental Health (NIMH) · 9 drugs
8. Centre for Addiction and Mental Health · 7 drugs
9. Alkermes, Inc. · 7 drugs
10. Ministry of Health & Welfare, Korea · 7 drugs

Key drug classes

• Atypical antipsychotic · 86
• Selective serotonin reuptake inhibitor (SSRI) · 36
• NMDA receptor antagonist · 27
• Benzodiazepine · 23
• Serotonin-norepinephrine reuptake inhibitor (SNRI) · 19
• Sympathomimetic amine; CNS stimulant · 17
• SSRI · 15
• Anticonvulsant / Mood stabilizer · 14
• Serotonin receptor antagonist · 11
• Norepinephrine-dopamine reuptake inhibitor (NDRI) · 10
• Sympathomimetic amine; central nervous system stimulant · 10
• Partial mu-opioid receptor agonist · 9
• atypical antipsychotic · 8
• Opioid receptor antagonist · 8
• Norepinephrine reuptake inhibitor (NRI) · 7

Subscribe

Get psychiatry / mental health approvals + PDUFA dates in your RSS reader:

• Psychiatry / Mental Health RSS feed · Atom · JSON

Other therapeutic areas